Evidence map›Paper›PMID 34371537›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].

R Jia, W X Wang, Y Y Gao, J Q Luan, F Qiao, J Y Liu, J H Yuan, Y Q Cheng, F S Wang, J L Fu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

R JiaMedical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
W X WangDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.
Y Y GaoDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
J Q LuanDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
F QiaoDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
J Y LiuDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
J H YuanDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Y Q ChengDepartment of Geriatric Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
F S WangMedical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.
J L FuMedical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.
Chinese PLA General Hospital · CN

Funding

National Natural Science Foundation of China 81572462, 81803299the capital health research and development of special 2016-2-5031, 2020-1-2181, 2018-2-2183the Innovation Groups of the National Natural Science Foundation of China 81721002The National Science and Technology Major Project 2017ZX10202201
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis B, ChronicHepatitis B Surface AntigensAntiviral AgentsChemokine CCL5DNA, ViralHepatitis B e AntigensHepatitis B virusHumansInterferon-alphaPolyethylene GlycolsTreatment OutcomeAntiviral AgentsChemokine CCL5DNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsChronic hepatitis BClinical cureInterferonRANTES

Identifiers

PMID34371537
PMCPMC12814125
OpenAlexW3191042842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.